The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis
Authors:
Open Access
- 11 November 2023
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115921
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and MetastasesPLOS ONE, 2013
- Evaluation of a Fluorescent Derivative of AMD3100 and its Interaction with the CXCR4 Chemokine ReceptorChemBioChem, 2011
- Labeling Live Cells by Copper-Catalyzed Alkyne−Azide Click ChemistryBioconjugate Chemistry, 2010
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditionsBlood, 2009
- Discovering and improving novel peptide therapeuticsCurrent Opinion in Pharmacology, 2008
- Click Chemistry, A Powerful Tool for Pharmaceutical SciencesPharmaceutical Research, 2008
- Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasionOncogene, 2006
- CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasionLaboratory Investigation, 2004
- Molecular Mechanism of AMD3100 Antagonism in the CXCR4 ReceptorJournal of Biological Chemistry, 2004